Global Blood Therapeutics Inc
Change company Symbol lookup
Select an option...
GBT Global Blood Therapeutics Inc
FNMA Federal National Mortgage Association
FLWS 1-800-Flowers.Com Inc
EQH Axa Equitable Holdings Inc
ENTX Entera Bio Ltd
ELAN Elanco Animal Health Inc
DLX Deluxe Corp
BPMC Blueprint Medicines Corp
HZN Horizon Global Corp
RDS.A Royal Dutch Shell PLC

Health Care : Biotechnology | Small Cap GrowthCompany profile

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

UPDATE: Aphria rises after Citron sells, MedMen sued by former CFO

10:40 am ET February 2, 2019 (MarketWatch)

By Max A. Cherney

CannabisWatch: The Green Organic Dutchman is still building but not selling, tiny weed producer wins POT ticker lottery

Short seller Andrew Left said early Friday he was exiting his position in Canadian cannabis producer Aphria Inc. and had begun to short Cronos Group Inc., citing its high valuation relative to analyst price targets.

Left's Citron Research said Dec. 18 that it expected Aphria shares to climb to $8 ( by the end of 2018, and in a Friday tweet said the stock had gained more than 60%. In the December report Citron said it expected Aphria to gain 40% by the end of last year. Aphria (APHA.T) (APHA.T) stock closed up 10% Friday, and has gained more than 80% since Citron made its call. Aphria said Friday ( that it has transferred plant cuttings from four weed straings to Denmark-based Schroll Medical. Aphria will now be one of the first pot growers to produce its own pot in Europe.

Citron did not return a request for comment.

In the same tweet, Citron said that it was short Cronos (CRON.T) (CRON.T) because the stock was trading 70% above sell-side analyst estimates. According to FactSet, there are seven analysts covering the name, with an average target price of $17.61. Including Friday's rise of 5.7%, Cronos is trading roughly 55% above the average target price, according to FactSet.

See also: Green Growth makes hostile bid for Aphria official (

Cronos stock rose 60% since it announced the $1.8 billion investment ( in the company by Marlboro-maker Altria Group Inc. (MO) Thursday, Altria's CEO said ( he expects the global cannabis market to reach $40 billion in 10 years with no new cannabis legalization laws, and $250 billion if pot were legal the world over. He said the company wasn't planning to stop at Cronos when investing in the industry.

Cannabis stocks largely gained Friday, with the Horizons Marijuana Life Sciences Index ETF rising 2.2%, and the ETFMG Alternative Harvest ETF(MJ) increasing 2% for the day. The world's largest pot company, Canopy Growth Corp. (WEED.T) (WEED.T), fell 0.2%, Aurora Cannabis Inc. (ACB.T) (ACB.T) was up 4.4%, and Tilray Inc. closed up 1.8%.

Other cannabis news

- MedMen Enterprises Inc. Chief Financial Officer James Parker, who resigned from his post in November amid an equity raise which it cut in half (, is suing ( the company in Los Angeles Superior Court for breach of contract and wrongful termination, among other things. At the time, MedMen refused to comment on the CFO departure and said cutting the financing nearly in half was due to a "significant selloff" in the global market. MedMen closed down 6.2% Friday.

The American pot retailer said early Friday that it expects to report fiscal second-quarter earnings Feb. 27 after the closing bell.

- Canadian weed producer The Green Organic Dutchman (TGOD.T) -- which has not yet sold any pot in the recreational market but is valued by investors at roughly $1 billion ( -- also rose Friday, after it said would be able to increase its capacity to grow cannabis to 202,500 kilograms a year from 156,000 kilograms a year at its facilities in Canada. However, the company also said several phases of construction would be complete either at the long-end of the company's previous projected schedule, or delayed until 2021. Dutchman stock closed up 4.3% in Friday trading.

Opinion: Two cannabis companies top Harry Boxer's stocks to watch (

- Weekend Unlimited Inc. said Friday that it was the winner of Canada's lottery for the POT ticker ( Weekend Unlimited is a tiny cannabis company with a market capitalization of $46 million and no revenue to speak of in 2018, according to FactSet.

"There has been tremendous excitement generated globally for the POT symbol. The POT lottery served to raise the profile of Canada's leadership in legal recreational cannabis and we believe it will also serve to raise Weekend Unlimited's leadership profile," Chief Executive Paul Chu said in a statement. Weekend Unlimited's over-the-counter shares rose 164% to close at $0.2159.

- Earlier this week Canada-based Organigram Holdings Inc. (OGI.V) said it had rolled ( more than one million joints.

-Max A. Cherney; 415-439-6400;

(END) Dow Jones Newswires

February 02, 2019 10:40 ET (15:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.